Trials / Completed
CompletedNCT01959269
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 483 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib (Stivarga, BAY 73-4506) | As determined by the treating physician |
Timeline
- Start date
- 2013-10-31
- Primary completion
- 2017-03-31
- Completion
- 2017-07-07
- First posted
- 2013-10-09
- Last updated
- 2018-03-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01959269. Inclusion in this directory is not an endorsement.